Early Days For Discovery Collaborations With Academia In China - China Healthcare Investment Conference
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Big Pharma and device companies are looking to test different models to harness a new source of novel technology as China's innovative life science sectors become more developed. Returnees, Chinese researchers and entrepreneurs that study or work in the West before establishing or working for companies in China, may have a large impact on how Western firms approach partnering in China
You may also be interested in...
Medtronic Launches New Facilities In Shanghai And Singapore; Thermo Fisher To Open Fifth China Plant
Medtronic Inc. raised its Asian profile last week with opening ceremonies for a regional headquarters building in Shanghai and a manufacturing plant in Singapore. The company plans to add 1,000 skilled staff to its China workforce in the next five years
Lilly Shifts Gears In China With New Shanghai-based R&D Center
Eli Lilly is deepening its commitment to China and diabetics in the country by opening a new R&D center in Shanghai that aims to discover novel compounds that will lead to breakthrough therapies for diabetes
Pfizer Signs Academic Collaboration Pact With Peking University To Support Translational R&D Center In Shenzhen
SHANGHAI - After unveiling a plan to build a research and development center in Wuhan last week, Pfizer announced it inked an agreement with Peking University Dec. 1 to fund the university's research projects and to build a translational research and drug discovery center in PKU's Graduate School in Shenzhen, a Chinese city that borders the former British enclave of Hong Kong